Organization
Yale University School of Medicine
28 abstracts
Abstract
Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors.Org: The University of Texas MD Anderson Cancer Center, Hospital Universitario 12 de Octubre, NCT Heidelberg, Charité Universitätsmedizin Berlin, Prisma Health Cancer Institute,
Abstract
Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial.Org: City of Hope Comprehensive Cancer Center, CanSino Biologics, Flagstaff, Yale University School of Medicine, CTI BioPharma,
Abstract
ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC).Org: David Geffen School of Medicine at UCLA, University of California, Los Angeles, Seoul National University Hospital, Korea University Anam Hospital, Korea University College of Medicine,
Abstract
Primary outcomes of the enhanced, EHR-facilitated cancer symptom control (E2C2) cluster-randomized, stepped wedge, pragmatic trial.Org: Mayo Clinic Department of Pediatric and Adolescent Medicine, Mayo Clinic, Indiana University School of Medicine and Regenstrief Institute, Yale University School of Medicine, National Cancer Institute/National Institutes of Health,
Abstract
Current management practices of de novo oligometastatic breast cancer: Real-world data from a physician survey.Org: Yale University School of Medicine, Yale Cancer Center, Yale School of Medicine,
Abstract
Correlation of hormone receptor positive HER2-negative/MammaPrint high-2 breast cancer with triple negative breast cancer: Results from gene expression data from the ISPY2 trial.Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, Yale University School of Medicine, Bioinformatics Support Program,
Abstract
Evaluation of the study of control arms in randomized clinical trials of cancer.Org: Brown University School of Medicine-Rhode Island Hospital, Memorial Sloan Kettering Cancer Center, Yale University School of Medicine, Saint Louis University School of Medicine, UNC Lineberger Comprehensive Cancer Center,
Abstract
Cost trends in standard-of-care cancer treatments, 2017-2021.Org: New York Presbyterian/Weill Cornell Medical Center, Memorial Sloan Kettering Cancer Center, University of Chicago, Harris School of Public Policy, Yale University School of Medicine, DELFI Diagnostics,
Abstract
SPPADE symptom prevalence and severity in a diverse sample of patients living with metastatic cancers.Org: Mayo Clinic, Indiana University School of Medicine, Regenstrief Institute, Mayo Clinic Florida, National Cancer Institute/National Institutes of Health,
Abstract
A descriptive patient-reported outcomes (PROs) analysis of KEYNOTE-412 to understand head and neck symptom burden.Org: Merck & Co., Inc., Gustave Roussy Cancer Center, Fondazione IRCCS Istituto Nazionale dei Tumori, Yale University School of Medicine, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.Org: Dana-Farber Cancer Institute, University of Chicago Medicine, UNC Lineberger Comprehensive Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Emory University Hospital,
Abstract
Trends in NCCN enforcement of financial conflict of interest policies for guidelines panelists.Org: Memorial Sloan Kettering Cancer Center, DELFI Diagnostics, University of Florida-Health Cancer Center, Orlando Health, Orlando, FL, Yale University School of Medicine, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA,
Abstract
Blood type as a risk factor for pancreatic ductal adenocarcinoma.Org: Yale University School of Medicine, VA Connecticut Healthcare System, Perelman School of Medicine, University of Pennsylvania,
Abstract
ERBB2 mutations and association with molecular phenotype in urothelial carcinoma.Org: Dana-Farber Cancer Institute, Yale University School of Medicine, Yale School of Medicine, Yale Cancer Center, Yale University,
Abstract
Impact of semaglutide and tirzepatide administration on weight in women with stage I-III breast cancer.Org: Yale University School of Medicine, Yale University, Yale Center for Analytical Sciences, Yale School of Medicine,
Abstract
Impact of β-adrenergic blockade on efficacy of immunotherapy in patients with metastatic clear cell renal cell carcinoma.Org: Dana-Farber Cancer Institute, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, Beth Israel Deaconess Medical Center, Yale University School of Medicine, The Lank Center for Genitourinary Oncology,
Abstract
A subset of neutrophils as a predictive biomarker for immunotherapy response in patients with non–small-cell lung cancer and melanoma.Org: Technion Israel Institue of Technology, Haifa, Israel, Israeli Medical Research Center, Technion - Israel Institute of Technology, Yale School of Medicine,
Abstract
The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.Org: Mount Sinai Health System, SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Dana-Farber Cancer Institute, SWOG Statistical Center,
Abstract
Longitudinal mutational analysis of TP53 in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, an MDM2–p53 antagonist.Org: Boehringer Ingelheim Pharma GmbH & Co. KG, Memorial Sloan Kettering Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Sarah Cannon Research Institute/Tennessee Oncology, Florida Cancer Specialists & Research Institute,
Abstract
A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101.Org: Memorial Sloan Kettering Cancer Center, University of Kansas Medical Center Department of Internal Medicine, NSABP/NRG Oncology and Wake Forest University Baptist Medical Center, Gettysburg Cancer Center, University of Arizona Cancer Center,
Abstract
Molecular predictors and immunomodulatory role of dual checkpoint inhibitor blockade using ipilimumab/nivolumab in patients with extensive stage small cell lung cancer.Org: Yale University School of Medicine, Ocean Genomics, Yale University Dept of Pathology, Yale School of Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT,
Abstract
Association between intra-tumoral microbiome and clinical benefit (CB) from immunotherapy (IO) in patients with metastatic renal cell carcinoma (mRCC).Org: City of Hope Comprehensive Cancer Center, Quantitative Medicine and Systems Biology Division, Translational Genomics Research Institute (TGen North), Integrated Cancer Genomics Division, Yale University School of Medicine,
Abstract
Investigating the impact of demographic disparities on clinical outcomes in cutaneous T-cell lymphoma (CTCL): A multicenter retrospective cohort analysis.Org: Emory University School of Medicine, Emory University, Department of Biostatistics and Bioinformatics, Johns Hopkins University School of Medicine, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Johns Hopkins University Bloomberg School of Public Health,
Abstract
A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumors: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS).Org: Yale University School of Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Memorial Sloan Kettering Cancer Center, Department of Experimental Therapeutics, National Cancer Center Hospital East, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
Neoadjuvant immunotherapy in hepatocellular carcinoma: A systematic review and meta-analysis.Org: Bridgeport Hospital, Yale New Haven Health, Bridgeport, CT, UMass Chan Medical School, Shrewsbury, MA,
Abstract
Decreased HER2 expression in residual disease following neoadjuvant therapy in patients with HER2-positive breast cancer.Org: Yale-New Haven Health, Yale University School of Medicine,
Abstract
Relations between mutant KRAS and TP53 subtypes and other co-mutations in pancreatic cancer.Org: Bridgeport Hospital, Yale New Haven Health, University of Pittsburgh, School of Medicine, Yale University Dept of Pathology, Yale University,
Abstract
Peripheral blood immune cell and cytokine profiling of patients receiving corticosteroids for immune checkpoint inhibitor-related adverse events: Steroid dose and duration.Org: Yale University School of Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Yale University, Yale School of Public Health,